Please note that for any DOS on or after 7/3/26, MA Medicaid will no longer cover the following drugs for weight loss and obesity indication. The updated coverage will apply MA UHC Community Health Plan.
What is not changing?
The drugs are still covered for indications that are covered by CMS: type 2 diabetes, obstructive apnea and cardiovascular disease.
The following drugs are affected:
- Contrave® (naltrexone/bupropion)
- Didrex (benzphetamine)
- Dietylpropion (diethylpropion extended release)
- Lomaira®, Adipex-P® (phentermine capsule, tablet)
- Mounjaro® (tirzepatide)
- Ozempic® (semaglutide)
- Phendimetrizine (phendimetrazine extended release)
- Qsymia® (phentermine/topiramate)
- Saxenda® (liraglutide)
- Wegovy® (semaglutide)
- Xenical® (orlistat)
- Zepbound® (tirzepatide)
If are a provider that accepts UHC MA community health mwmbers in your office and has any of the CMS covered DXs and no auth, please click here to request one.
Find this information useful? Follow my blog fpr more!
Need a medical coding/billing/reimbursement guide? Click here for CART-T.
- MA medicaid weight loss drug coverage update
- Aetna: usage of modifier CT and reimbursement
- NYS Medicaid: Article-29 VFCA medical billing changes
- SOMOS IPA and EmblemHealth to term relationship
- NY State PDN services updates: new forms
KR2 Medical Billing 
Leave a comment